Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: margie who wrote (5563)	10/21/1998 5:11:00 PM
From: Izzy	Read Replies (2) of 6136

Rick (or anyone): Any comment regarding AG1766 protease inhibitor (RE: Post 5563)? We've mentioned this before and it was my previous understanding that AGPH was attempting to improve Viracept. Is this a new PI? Do you have any info? I can't find out anything about it and I haven't seen it referenced before as AG1766. I assume that this is not the PI from Japan. Potentially, that would mean that AGPH will have 2 PIs, one NNRTI, and Remune on the market as early as mid-late 1999. Does this imply that "AGPH General" will actually end up being a monster HIV drug powerhouse? And it seems strange to me that there has been no mention of the oncology division spinoff. Also, I haven't received the shareholders' meeting package yet. Has anyone else received it?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next